Prestige Brands Expects OTC Assets Will Shake Loose From M&A Activity
This article was originally published in The Tan Sheet
Executive Summary
“If you looked at it based on history,” consolidation has created opportunities to acquire OTC brands, says Prestige Brands CEO Matthew Mannelly. The firm’s interest in adding brands is “stronger than ever,” he adds.
You may also be interested in...
In Brief: Prestige Buys Insight, Quarterly Earnings For MJN And Colgate, Bio-Recovery Warned On Claims
Prestige acquires Insight Pharmaceuticals; Product relaunches boost Novartis’ consumer sales; Colgate’s N.A. sales inch up; Mead Johnson sales up 7%; and Bio-Recovery makes drug claims.
Genomma Refuses To Raise Price, Drops Prestige Bid
Genomma drops its unsolicited offer because it was unwilling to meet Prestige’s demand for a higher price. The Mexican firm said it secured funding and met other milestones Prestige insisted on.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.